Michelle Longmire, Medable CEO (Photo Credit: Jeff Rumans)

Two de­cen­tral­ized tri­als star­tups prove they're not im­mune to broad­er wave of biotech lay­offs

Af­ter rais­ing heaps of cap­i­tal dur­ing the first two years of the Covid-19 pan­dem­ic to help bio­phar­mas shift to vir­tu­al clin­i­cal stud­ies, a few de­cen­tral­ized clin­i­cal tri­als providers have con­duct­ed lay­offs in re­cent months as they ad­just busi­ness pri­or­i­ties, End­points News has learned.

That in­cludes pri­vate­ly held Med­able, which dis­closed a $304 mil­lion Se­ries D last Oc­to­ber, and Sci­ence 37, which al­so be­gan trad­ing last Oc­to­ber af­ter a SPAC merg­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.